National and Kapodistrian University of Athens
Συμβολή στην ανεύρεση του καλύτερου δοσολογικού σχήματος ιντερφερόνης (40MUI, 60MUI, 80MUI) για την προφύλαξη από τις υποτροπές των επιφανειακών όγκων της ουροδόχου κύστης, μέσης κακοήθειας
Abstract
dc:descriptionThe purpose of this study was to define the best and most effective dosimetry of intravercical in stilation with Interferon alpha-2b for preventing the recurrences tumours of middle-malignancy of the urinary bladder. Bladder cancer is the second most prevalent urological malignancy and is characterized by diverse biological behaviour. This causes a dilemma as to whether conservative or aggressive treatment should be offered. Approximately 70-85% of bladder cancer patients have superficial (Ta, Τ₁, and/or Ca in Situ) tumours at the time of clinical presentation. Superficial bladder cancer is characterised by a high recurrence rate ranging from 50-80%, most frequently in the first year after transurethral resection (TUR) of the tumour. Even more a threatening is the risk of tumor progression towards invasive cancer which is estimated to occur in 20-25% of the superficial tumours. Today the most prognostic parameters that have been studied give us only general guidelines on how to clinically deal with such cases and none of them provide us with creditable, information associated with prognosis of a specific tumor. The study was done on 89 patients (20 controls and 69 patients with intravesical instillations of Interferon a-26) with a mean age of 61, 62 (±9,63) years from which 65 patients (73,3%) were shown to have a single tumor whereas 24 patients (26,7%) were shown to have multiple tumors, (multifocal disease). The patients were separated and were classified randomly (the use of a table of random numbers) into 4 groups (A, B, C, D) consisting of 20, 22, 24, and 23 patients respectively. The patients were received as a six weeks induction phase weekly inflations by interferon-a-26, there after a fortnightly instillation for three (3) months and then monthly instillations for the remaining (6) six months of the treatment period. A solution of Interferon alpha-2b, with concentrations of 40, 60 and 80 M.U.I, more for intravesical administration diluted into 50ml natural water solution, was used in groups B, C ,D respectively while the control group (group A) was treated only with TUR. The studied parameters in the current trial for groups A, B, C, D respectively were: - The time complesive of observation was 447, 675, 755. 798 months. - The overall follow-up period until relapse occurred was 195,171,183,150 months. - The total number of pts who recurred was 13, 8,7,5. - The percentage of patients who relapsed was 65,36.36, 29.77 & 21.74%. - The mean time in which a relapse occurred was 15, 21.38, 26.14, 30 months. - The recurrence rate per a 100 patient - months was 2.91,1.19, 0.88, 0.63 whereas the relative relapse index was 1.54, 0.69, 0.52, 0.37. - A higher stage after the relapse was observed in 6,3,1,1 patients while the patients free from disease were 7 patients (35%), 14 (63,63%), 17 (70,82%), 18 (78,76%). The commonly used clinical & laboratory examinations were performed to patients in order to diagnose the bladder tumour. The tumor staging was mainly based on; both hand-examination of the urinary, bladder, on computerized scan tomography of the lower and upper abdominal cavity, on transurethral resection (TUR) of the tumour and on the biopsy. Even though the most effective treatment protocol of intravesical infusions, with Interferon for profilaxis and treatment of superficial neoplasms of the Urinary bladder hasn't been established, Interferon has shown to be one of the most effective treatments to deal with cancers of the urinary bladder today. Several clinical studies have shown the superiority of this medicine in comparison with other chemiotherapeutic drugs. The duration of follow up period in this study was 6 to 36 months. Re-examination was done every 3 months with urine cytologic tests, cystoscopy and random biopsies on the epitheliums of urinary bladder. Also patients were followed-up during their instillations for any undesirable side-effects that would have appeared form the drug subjectively or from other pathological laboratory tests. With the aforementioned treatment 49 patients (while 7 from group A) from the 69 which constitute groups B, C, D (20 from group A) were shown to have cured and were free from disease after their treatment. Therefore 35% of the patients were free from disease in group A, 61,64% in group B, 70,83% in group C and 78,26% in group D. The remaining 20 patients from groups B, C, and D (while 13 from group A) relapsed, on contrary 5 patients from groups B, C, D and 6 from group A developed infiltrative urinary bladder tumours and then treated adequately. Side-effects were not observed in any subject at all after the drug instillation. Finally, we conclude that: 1) the IFN instillations decrease the recurrence rate, but they do not affect the progression and invasion of bladder tumour when compared with controls; the patients who received IFN had a lower recurrence rate, a smaller number of TUR, a shorter hospitalization period and additionally they costed fewer than the controls; 2.) The administration of 40 MIU IFN intravesically had not a beneficial effect as compared with others. The therapeutic effect of C and D IFN doses did not differ with statistically significance, as regard all studied parameters, except from the relative risk of recurrences. Considering the above, and because of the side effects were not dose-dependent, it could be concluded that the 80 MIU IFN intravesically (D dose) had a better clinical effect In addition, the dose D costs much more than the C one. Consequently, the proposal dose is difficult to be selected.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 1995
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Gekas, Aristomenis
- Γκέκας, Αριστομένης
Subjects
dc:subject × 10Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/6099